Updated 12:17 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 58,232.43 -0.96%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $58,232 −0.96% VIX 35.89 +26.20% latest tape · as of 12:17 UTC
The Screen · Healthcare · Biotechnology

Odyssey Therapeutics, Inc.

ODTX · Nasdaq · USD · Market cap $878M · 100 employees

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases.

FAIL · Does not pass the screen
16.96 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 12:17 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price16.96 USD at the 20 Nov 2026 close
  • Fair valueUnder review: our model's value is 2.06x the price, above our 2.00x limit.
  • Our regime readAccumulation, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: range not available (screen dated 2026-11-20).

Current read
Accumulation ?
Screened · screened 2026-11-20
  • Trend Accumulation
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options no verdict drawn today, left as found
  • Ethical does not pass the values gate
Price16.96 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-11-12Read Accumulation20.99-19.2% to today Markdown gives way to Accumulation after a 26% rise in 2 weeks
2026-10-27Read Markdown16.60+2.2% to today Distribution gives way to Markdown after a 29% slide in 5 weeks
2026-09-24Read Distribution23.34-27.3% to today ✓First review on file: Distribution

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its accumulation label.

Odyssey Therapeutics, Inc. holds its Accumulation at $16.96. Consolidating, no directional conviction, held for 1 days.

As held on the ledger · 2026-11-20
PhaseAccumulation
Quantitative stateConsolidating, no directional conviction, held for 1 days
Price at the screen$16.96
ValuationN/A trailing · -4.40 forward price to earnings
Values screenFAIL · score 70.0
The Workings

Five Screens: ODTX's Results

FAIL. Revenue purity

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 10.05% Below 33% Pass
Interest-bearing cash 13.05% Below 33% Pass
Receivables 15.45% Below 49% Pass
Revenue purity 100.00% Below 5% Fail

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

Odyssey Therapeutics, clears the business-activity screen, and its debt is inside the line. Where it falls short is income purity: around 100% of its income right now is interest earned on a large cash position, against a roughly 5% ceiling, so it does not pass. That reflects what it earns today, not the business itself, and it could clear the screen if its operating revenue grows and the interest share falls.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when ODTX's ethical verdict changes

Today ODTX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Fair value under review. Our model's value is 2.06x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.

Method.

The Street's Range
27.00Street low 35.00Street average 44.00Street high 16.96Price

Street: 6 covering, consensus Strong Buy. Average target +106%.

Chart
The Business, in Plain Words
The fundamentals · plain-English read
Forward P/E-4.4x
EPS, trailing-7.55
EPS, forward-4.15
Profit margin0.0%currently unprofitable
Debt to equity0.06minimal debt: a conservative balance sheet
Current ratio11.36comfortably covers its short-term bills
Short interest, float0.07%
52-week range15.10 - 29.05
Market cap$878M
Employees100

ODTX-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Accumulation $18.98 -9.6% Entry 14
2026-11-12 Accumulation · changed $20.99 +7.6% Entry 13

The framework has shifted from markdown to accumulation since the last review.

2026-11-05 Markdown $19.50 -9.6% Entry 12
2026-11-04 Markdown $21.57 +10.4% Entry 11
2026-11-03 Markdown $19.54 +0.0% Entry 10
2026-11-02 Markdown $19.54 +0.0% Entry 9
2026-11-01 Markdown $19.54 -0.3% Entry 8
2026-10-31 Markdown $19.60 +0.0% Entry 7
2026-10-30 Markdown $19.60 +0.0% Entry 6
2026-10-29 Markdown $19.60 +18.1% Entry 5

Earnings landed in this window. Ethical screening: FAIL.

Written on its date, before the outcome; never pruned.

Related Securities · Others in ODTX's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $17.45 -6.9% · $932 -6.9%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever ODTX does next, these words stay.

Odyssey Therapeutics, Inc. · ODTX · Accumulation · $16.96
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.